Stock Information

Symbol

NASDAQ: SCMP

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products - AMITIZA, its lead product, and RESCULA - and a late-stage pipeline of product candidates in clinical development for orphan disease areas.  VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1.  Sucampo has an option for the North American rights to CPP1-x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S.  A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.

Contact Information

Investor Relations
Silvia Taylor
Senior Vice President, Investor Relations and Corporate Affairs
T: 240-223-3718
investor@sucampo.com

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
T: 718-921-8200
info@amstock.com